Xeomin and Botox Cosmetic are botulinum toxin type A medicines used to temporarily soften certain expression lines. They differ in formulation, but that difference alone does not tell you which will give you a better result. A useful comparison separates what is in the vial from what clinical studies have actually tested.
For someone considering either product, the central questions are straightforward: what does “purified” mean, what does the evidence say about results, and what should change in the conversation if you are switching treatments?
What differs in the ingredients?
Xeomin contains incobotulinumtoxinA; Botox Cosmetic contains onabotulinumtoxinA. Both are manufactured from botulinum toxin type A. In Xeomin, manufacturing separates the active neurotoxin from accompanying bacterial proteins, often called accessory or complexing proteins. Botox Cosmetic contains the neurotoxin together with accessory proteins.
| Formulation detail | Xeomin | Botox Cosmetic |
|---|---|---|
| Active ingredient | IncobotulinumtoxinA | OnabotulinumtoxinA |
| Accessory proteins accompanying the neurotoxin | Removed during purification | Present in the neurotoxin complex |
| Listed inactive ingredients | Human albumin and sucrose | Human albumin and sodium chloride |
These details come from the Xeomin prescribing information, revised June 2026 and Botox Cosmetic prescribing information, revised October 2024.
This is why calling Xeomin “naked” can be misleading without an explanation. It does not mean the vial contains only the active ingredient, or that the medicine is protein-free. Human albumin is itself a protein. “Without accessory proteins” describes a particular manufacturing difference; it is not a complete description of the formulation.
Does purification mean better results or fewer reactions?
Removing accessory proteins does not, by itself, establish that Xeomin will last longer, work faster or cause fewer allergic reactions than Botox Cosmetic. Both products carry warnings about hypersensitivity. A previous reaction deserves a discussion about the actual product and its components, rather than reassurance based on the word “purified.”
Allergy and reduced treatment response are also different questions. The Xeomin label explains that antibody results depend on the testing method, so rates from separate studies cannot be used as a reliable brand ranking. The absence of accessory proteins should not be presented as a guarantee against antibodies or future loss of effect.
If a treatment seems less effective, describe what changed: the area, the visible movement, when the effect appeared and how long it lasted. That gives the clinician a more useful starting point than assuming the brand has “stopped working.”
What have direct comparisons shown?
A 2023 randomized, double-blind study in China compared the two medicines in adults with moderate to severe glabellar lines—the frown lines between the eyebrows. At day 30, Xeomin met the study’s predefined noninferiority criterion: the main analysis ruled out it performing worse than Botox by more than the trial’s chosen margin.
That finding supports effectiveness in the situation studied. It does not prove the products are identical, establish that Xeomin is superior, or settle which will last longer for every person or treatment area. The study was funded by Merz, Xeomin’s manufacturer; several authors were current or former employees, and another disclosed a consultancy relationship.
An earlier randomized comparison published in 2012 used a different treatment regimen. It found similar response at day 28, but equivalence was not established at later assessments. These are different studies with different questions, not two entries that can be combined into a universal winner’s table.
The practical lesson is to ask what a comparison measured. Frown lines at a specified follow-up, forehead movement, speed of onset and duration are different outcomes. Evidence for one does not automatically answer the others.
What should you ask before choosing or switching?
Bring the name of your previous product, the treatment date and any record of your response. Then ask:
- Which exact product and area are we discussing? Ask why it fits your goal and whether that use is authorized locally.
- What is the reason for switching? Make the desired change specific, such as the appearance or movement you want assessed.
- Does my history change the choice? Mention previous reactions, relevant medical conditions and all medicines you take.
- What does the quoted plan include? Clarify the product, areas, assessment and follow-up, rather than comparing a price per unit in isolation.
Both labels state that their potency units are product-specific and cannot be converted into another brand’s units. A study using particular regimens is not a conversion chart for your next appointment.
U.S. labeling does not establish authorization in Mexico. Our guide to botulinum toxin brands, authorization and safety explains the broader checks, including the exact Mexican registration and product traceability.
Both medicines carry a warning about toxin effects spreading beyond the injection site. Seek immediate medical attention for difficulty breathing, speaking or swallowing after treatment. Review the full product information with your treating clinician before proceeding.